Cosmetic use of an extract of Lysimachia christinae

Abstract

Cosmetic Use of a Lysimachia christinae Extract The present invention relates to the non-therapeutic cosmetic use of a Lysimachia christinae extract to improve and / or maintain the biomechanical properties of the skin and / or mucous membranes. It further relates to a non-therapeutic cosmetic treatment method using the Lysimachia christinae extract or a composition containing it.

Description

Title of the invention: Cosmetic use of an extract of Lysimachia christinae. Technical field

[0001] The present invention relates to the non-therapeutic cosmetic use of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or mucous membranes. In particular, the use according to the invention makes it possible to improve and / or maintain the firmness and / or tone and / or density and / or thickness of the skin and / or mucous membranes. The invention also makes it possible to improve and / or maintain the radiance of the complexion of healthy skin and / or mucous membranes.

[0002] Furthermore, the present invention also relates to a cosmetic treatment method comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae and / or a cosmetic composition containing it to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes. The method according to the invention is for improving and / or maintaining the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis of healthy skin and / or healthy mucous membranes. The invention further enables the improvement and / or maintenance of the radiance of the complexion of healthy skin and / or healthy mucous membranes. Previous technique

[0003] The structure and properties of the skin change under the effect of complex biological, physical and biomechanical processes, resulting in a loss of its firmness and tone as well as a decrease in the density and thickness of the dermis, in particular under the effect of the decrease in the collagen level of the extracellular matrix.

[0004] The extracellular matrix of the skin and mucous membranes is composed of four types of molecules: collagen and elastin fibers, glycoproteins, and highly hydrated polysaccharides that form a gel-filling matrix. Collagen fibers play a predominant role in maintaining the structure and properties of the skin and mucous membranes, particularly their firmness and tone, and give the dermis its thickness and density.

[0005] Collagen is synthesized by fibroblasts. This protein, a constituent of the extracellular matrix (ECM), is present in large quantities in vertebrate tissues. It is a large family comprising 29 different types. Among the different types of collagen, type I collagen is found in particular in Many human tissues, such as tendons, ligaments, cornea, and skin, contain collagen, located more specifically in the dermis. Type I collagen is the predominant type of collagen in the skin and mucous membranes. Fibrillar collagen is formed from procollagen fibers, which are then assembled into a network and stabilized by cross-linking. Collagen gives tissues their mechanical strength and, consequently, contributes to maintaining their firmness and tone. Under the influence of various intrinsic and / or extrinsic factors, collagen levels can decrease, leading to a loss of firmness and tone in the skin and / or mucous membranes, as well as a decrease in the density and thickness of the dermis, and therefore in the skin and / or mucous membranes.

[0006] Matrix metalloproteinases (MMPs) constitute a family of 23 proteases that degrade all components of the extracellular matrix. In particular, the degradation of collagen by matrix metalloproteinases, especially types I and III, leads to a loss of firmness and tone, and a decrease in the thickness and density of the dermis of the skin and / or mucous membranes. Thus, the modulation of their expression actively participates in tissue remodeling and changes in the biomechanical properties of the skin and / or mucous membranes.

[0007] There is therefore a constant need in the field of cosmetics for alternative natural active ingredients, capable of improving and / or maintaining the biomechanical properties of healthy skin and / or healthy mucous membranes, in particular their firmness, tone and the thickness and density of their dermis.

[0008] The Applicant has discovered in a particularly surprising and unexpected way that an extract of Lysimachia christinae, in particular of the aerial parts, and preferably of the leaves, makes it possible to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes, in particular their firmness, their tone and the thickness and density of their dermis.

[0009] The plant Lysimachia christinae belongs to the genus Lysimachia and the family Primulaceae. Native to China, it is a creeping, perennial, and fast-growing herbaceous plant that can reach 20 to 60 cm in height. It forms clumps by developing its network of roots and creeping stems. The leaves are green, oval to orbicular or even kidney-shaped, hairless and glossy, alternate with petioles 1 to 3 cm long. The stems are slender, grayish-green or reddish-purple in color. The flowers are yellow, solitary, bell-shaped, with 5 oval to lanceolate lobes and 5 stamens. The plant is hermaphroditic and is pollinated by insects. It flowers from May to June and produces fruit from July to October.

[0010] An extract of Lysimachia christinae has been described for its properties on keratinocytes, through its restorative and hydrating action on the epidermal barrier (Hyun et al., Evaluation of the Skin Barrier Strengthening and Moisturizing Ability of Lysimachia christinae Hance Extract, The Korean Society of Culture and Convergence, December 2020. Vol.42, No. 12).

[0011] On the other hand, to the Applicant's knowledge, no prior art discloses or suggests an extract of Lysimachia christinae for cosmetic use or a cosmetic care process to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes, much less to improve and / or maintain the firmness and / or tone of healthy skin and / or healthy mucous membranes and / or the density of the dermis and / or the thickness of the dermis of healthy skin and / or healthy mucous membranes. Summary of the invention

[0012] A first object of the invention thus relates to the non-therapeutic cosmetic use of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0013] A second object of the invention relates to a non-therapeutic cosmetic care method comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae or of a cosmetic composition comprising it, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes. Description of the implementation methods

[0014] Cosmetic use

[0015] A first object of the invention relates to the non-therapeutic cosmetic use, advantageously by topical route, of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0016] In particular, the non-therapeutic cosmetic use, advantageously by topical route, of an extract of Lysimachia christinae, is to maintain and / or improve the firmness and / or tone of healthy skin and / or healthy mucous membranes and / or the density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes, preferably the firmness of healthy skin and / or healthy mucous membranes.

[0017] Advantageously, the use according to the invention, particularly by topical route, is therefore to increase and / or maintain the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers. Even more preferably, the use according to the invention, particularly by topical route, is to increase the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0018] Advantageously, the use according to the invention, particularly by topical route, is to increase and / or maintain the synthesis of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers. Even more preferably, the use according to the invention, particularly by topical route, is to increase the synthesis of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0019] Advantageously, the use according to the invention, particularly by topical application, is to inhibit the degradation of collagen, especially type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0020] Advantageously, the use according to the invention, particularly by topical application, is to inhibit the degradation of collagen, especially type I collagen, preferentially of collagen fibers, more preferably of type I collagen fibers, by decreasing the amount of matrix metalloproteinase(s) (MMP), particularly type I matrix metalloproteinase(s) (MMPI) and / or type III (MMP3).

[0021] Advantageously, the use according to the invention, particularly by topical application, is to inhibit the degradation of collagen, especially type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers, by inhibiting the synthesis and / or secretion of matrix metalloproteinase(s) (MMP), particularly type I matrix metalloproteinase(s) (MMPI) and / or type III (MMP3).

[0022] Advantageously, the use according to the invention, particularly by topical route, is to increase and / or maintain, advantageously increase, the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers, by increasing and / or maintaining, advantageously by increasing, collagen synthesis and by inhibiting its degradation, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0023] Another alternative object of the invention relates to the non-therapeutic cosmetic use, advantageously by topical route, of an extract of Lysimachia christinae to further maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, preferably by increasing and / or maintaining the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

[0024] For the purposes of the present invention, "cosmetic use" means a non-therapeutic use, that is to say, a non-pharmaceutical or non-dermatological use, in other words, a use that is not intended for a therapeutic purpose. therapeutic nor for the prevention and / or treatment of skin and / or mucous membranes classified as pathological by a specialist in the field, such as a dermatologist, but is intended for and / or applied to an area of ​​skin and / or mucous membrane(s) said to be healthy.

[0025] For the purposes of the present invention, "topical route" means the direct local application and / or vaporization of the extract according to the invention or of a composition comprising it according to the invention on the surface of the area of ​​skin and / or mucous membranes to be treated.

[0026] For the purposes of the present invention, "skin" means any part of the body and / or face, including the scalp. The term "skin" advantageously includes normal, oily, and combination skin. The skin may be Caucasian, African, and / or Asian.

[0027] For the purposes of the present invention, "mucous membrane" means the nasal and / or ocular and / or oral and / or gingival and / or labial and / or vaginal and / or anal and / or urogenital mucous membrane, advantageously the ocular and / or oral and / or labial and / or nasal mucous membranes, more advantageously the labial mucous membrane.

[0028] For the purposes of the present invention, "skin and / or mucous membrane(s)" are healthy, meaning that the skin or mucous membrane is considered "non-pathological" by a dermatologist, that is, it does not require therapeutic treatment, in other words, it does not present any infection, scar, particularly keloid scar, inflammation such as sunburn, xerosis, wound, injury, boils, or any skin disease or condition such as candidiasis, impetigo, psoriasis, eczema, acne, or dermatitis, particularly atopic dermatitis, and / or other dermatoses, rosacea, telangiectasia, solar elastosis, and / or cutis laxa. For the purposes of the present invention, healthy skin or healthy mucous membranes are not atopic.In particular, healthy skin or healthy mucous membranes according to the invention are not susceptible to developing acne and / or psoriasis and / or eczema and / or xerosis and / or dermatitis, in particular atopic dermatitis and / or keratosis and / or ichthyosis and / or cheilitis and / or couperose and / or telangiectasias, and / or keloid scars and / or cutis laxa pathology and / or impetigo.

[0029] Advantageously, the skin and / or mucous membrane according to the invention is not dry skin and / or mucous membrane and / or skin and / or mucous membrane with an impaired and / or weakened barrier function. In particular, it is not sensitive and / or atopic and / or reactive and / or sensitized skin and / or mucous membrane.

[0030] Within the scope of the present invention, the extract according to the invention is useful for maintaining and / or improving the biomechanical properties of the skin and / or mucous membranes and / or preventing the decline of these properties. The use according to the invention is not therefore not for hydrating the skin and / or mucous membranes, and / or protecting the skin and / or mucous membrane barrier and / or as an antioxidant.

[0031] For the purposes of the present invention, "biomechanical properties of healthy skin and / or mucous membranes" means the compressive strength and / or tensile strength and / or extensibility and / or resistance to deformation of healthy skin and / or mucous membranes. Preferably, this refers to the firmness and / or tone of healthy skin and / or mucous membranes and / or the density and / or thickness of the dermis of healthy skin and / or mucous membranes, and even more preferably, to the firmness of healthy skin and / or mucous membranes.

[0032] For the purposes of the present invention, "firmness of healthy skin and / or mucous membranes" means the ability of healthy skin and / or mucous membranes to resist deformation. Firmness can, for example, be measured using conventional techniques known to those skilled in the art. By way of example, firmness can be measured in vivo using devices such as an indentometer and a cutometer. The indentometer measures the depth of skin deformation using a ball; the shallower the depth, the firmer the skin. Preferably, firmness is measured according to the protocol in Example 4, and more particularly according to Example 4b.

[0033] The term "improving the firmness of healthy skin and / or mucous membranes" means a significant increase in the firmness value measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract, particularly under the conditions of Example 4b. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0034] The term “maintaining the firmness of healthy skin and / or healthy mucous membranes” means preventing and / or preventing the decrease in the firmness of healthy skin and / or healthy mucous membranes, particularly under the effect of aggressive agent(s).

[0035] For the purposes of the present invention, "tonicity of healthy skin and / or mucous membranes" means the tone of healthy skin and / or mucous membranes after a series of deformations, and corresponds to the inverse of "fatigability" or fatigue. It indicates the capacity of healthy skin and / or mucous membranes to deform and return to their original state after a series of deformations, typically after 10 or more deformations. On a graph representing the amplitude of the measured deformations on the ordinate and time on the abscissa, tonicity is the area of ​​the region located inside the curves that encompass the series of deformations and returns after deformation, and designated F3 as described in the DOBREV publication (Application of Cutometer area parameters for the study of human skin fatigue, Skin Research and Technology, 2005, 11:120-122). This area is therefore the logarithmic mean Maximum and minimum amplitudes. Therefore, tonicity is not the same as elasticity, which represents the ability of healthy skin and / or mucous membranes to return to their original state after a single deformation. The more tonic healthy skin or mucous membranes are, the less they tire over time. Finally, the larger the area of ​​the logarithmic mean of the maximum and minimum amplitudes, the more tonic the healthy skin and the less fatigued it is. Tonicity can be measured, for example, in vivo using a Cutometer®. This device measures the mechanical properties of the skin by recording the deformation of the skin through suction and its return to its original state.In particular, the tonicity of healthy skin can be measured by performing a series of deformations, typically 10 or more, and recording the area of ​​successive deformations and returns, that is, the area defined as the logarithmic mean between the maximum and minimum deformation values. Thus, the greater the number of deformations, the greater the tonicity. Preferably, tonicity is measured according to the protocol in Example 4, particularly Example 4a.

[0036] The term "improving the tone of healthy skin and / or mucous membranes" means a significant increase in the measured tone value after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract, particularly under the conditions of Example 4a. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0037] The term "maintaining the tone of healthy skin and / or healthy mucous membranes" means preventing and / or preventing the decrease in the tone of healthy skin and / or healthy mucous membranes, particularly after successive deformations, especially under the effect of aggressive agent(s).

[0038] For the purposes of the present invention, "density (of the dermis) of healthy skin and / or healthy mucous membranes" means the protein content of the extracellular matrix synthesized by fibroblasts, in particular collagen fibers, and even more preferably type I collagen fibers. The density can be measured, for example, in vivo and ex vivo (biopsy) according to conventional methods, in particular by ultrasound.

[0039] “Improving the density (of the dermis) of healthy skin and / or mucous membranes” means a significant increase in the density value measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0040] The term "maintaining the density (of the dermis) of healthy skin and / or healthy mucous membranes" means preventing and / or stopping the significant decrease in the density value in the dermis, in particular collagen fibers, even more preferably type I collagen fibers, of healthy skin and / or healthy mucous membranes, particularly under the effect of aggressive agent(s).

[0041] For the purposes of the present invention, "thickness of the dermis of healthy skin and / or healthy mucous membranes" means the total height of the dermal layer of healthy skin and / or healthy mucous membranes. Dermal thickness can, for example, be measured in vivo using ultrasound.

[0042] The term "improving the thickness of the dermis of healthy skin and / or mucous membranes" means a significant increase in the total dermal height measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0043] The term "maintaining the thickness of the dermis of healthy skin and / or healthy mucous membranes" means preventing and / or stopping the decrease in the total height of the dermis of healthy skin and / or healthy mucous membranes, particularly under the effect of aggressive agent(s).

[0044] For the purposes of the present invention, "inhibiting collagen degradation" means decreasing or preventing the increase in the amount of matrix metalloproteinase(s), particularly type I (MMPI) and / or type III (MMP3) matrix metalloproteinase(s), notably by decreasing and / or preventing the increase in their synthesis and / or secretion in the dermis, particularly under the effect of aggressive agent(s). Collagen degradation can be measured using conventional techniques known to those skilled in the art, in particular according to the protocol described in Examples 3a) and 3b).

[0045] For the purposes of the present invention, "radiance of the complexion of healthy skin and / or healthy mucous membranes" means the ability of healthy skin and / or healthy mucous membranes to reflect light, and in particular refers to the radiance and / or luminosity of healthy skin and / or healthy mucous membranes. The luminosity of healthy skin and / or healthy mucous membranes can be measured in vivo using a Chromameter and corresponds to the value L. The measurement of the radiance of healthy skin and / or healthy mucous membranes can, for example, be carried out in vivo using a Glossimeter®. The latter projects light onto the healthy skin or healthy mucous membranes and measures its reflection at a precise angle. The greater the reflection, the more radiant the healthy skin. Preferably, radiance is measured according to the protocol of Example 4, particularly Example 4c.

[0046] Advantageously, "improving the radiance of healthy skin and / or mucous membranes" means a significant increase in radiance value and / or an increase in luminosity, measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to untreated healthy skin and / or mucous membranes, radiance being measured in particular under the conditions of Example 4c. Significance can be assessed by appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05. Preferably, radiance is measured after 56 days of application, preferably with two applications per day.

[0047] The term "maintaining the radiance of the complexion of healthy skin and / or healthy mucous membranes" means maintaining the radiance and / or luminosity of healthy skin and / or healthy mucous membranes and / or preventing the decrease in radiance and / or luminosity of healthy skin and / or healthy mucous membranes, including under the effect of aggressive agent(s).

[0048] The extract according to the invention is an extract of Lysimachia christinae.

[0049] The extract according to the invention has the advantage of being a cosmetically acceptable active ingredient that does not irritate the skin and exhibits high chemical stability. It does not cause allergies. This extract can be produced on an industrial scale.

[0050] Advantageously, the extract according to the invention is topically acceptable. For the purposes of the present invention, "topically acceptable" means an ingredient suitable for topical application, non-toxic, non-irritating to the skin and / or mucous membranes, which does not induce an allergic response and is not chemically unstable.

[0051] The extract according to the invention is obtained from Lysimachia christinae. Advantageously, the Lysimachia christinae extract according to the invention is an extract of aerial parts, even more advantageously of leaves.

[0052] For the purposes of the present invention, aerial parts include, in particular, stems, flowers, leaves, fruits, seeds and mixtures thereof. They do not include roots. Preferably, they refer to stems and leaves, and even more preferably to leaves.

[0053] Advantageously, the extract according to the invention is therefore not a whole plant extract. Advantageously still, the extract is not a root extract.

[0054] The extract according to the present invention is obtained by any extraction method known to those skilled in the art, chosen from among hot decoction, maceration, extrusion, subcritical extraction, and ultrasonic-assisted extraction, with or without grinding such as ultrasonic grinding or grinding with a mixer. Advantageously, the extract is obtained by maceration and more advantageously by maceration under agitation.

[0055] "Subcritical extraction" means extraction in the presence of water, under conditions of temperature above 100°C and pressure less than or equal to 22.1 MPa (221 bars), such that the water remains in a liquid state but has a viscosity and surface tension lower than that of water at room temperature, increasing its dielectric constant.

[0056] The extraction can be carried out from dry or fresh plant material, advantageously dry, in quantities of 1% to 90% by weight, advantageously from 2% to 50%, very advantageously from 3% to 25%, preferably from 4% to 10%, even more preferably from 6% to 9%, even more preferably from 7.5%, by weight of plant material in relation to the total weight of the plant material and the extraction solvent.

[0057] The extraction can be carried out at a temperature ranging from 4°C to 300°C, including ambient temperature, i.e. a temperature of about 20°C. In a preferred embodiment of the invention, the extraction will be carried out at a temperature ranging from 20°C to 150°C, preferably from 20°C to 90°C, particularly from 70°C to 90°C, preferably from 75°C to 85°C, more preferably from 80°C.

[0058] The extraction can be conducted for a period of a few seconds to 24 hours, preferably from 1 minute to 12 hours, even more preferably for a period of 5 minutes to 5 hours, more preferably for a period of 0.5 hours to 3 hours, even more preferably for one hour.

[0059] The extraction can be repeated as many times as necessary with identical or different conditions from the first extraction, preferably the extraction is not repeated.

[0060] Advantageously, the extract according to the invention is obtained by extraction in a solvent or a mixture of protic polar solvent(s), advantageously in water, an alcohol, a glycol, a polyol or a mixture thereof, advantageously also in water as the sole solvent.

[0061] For the purposes of the present invention, "protic polar solvent" means a solvent having a dipole moment and at least one hydrogen capable of participating in hydrogen bonding.

[0062] The extraction solvent can be chosen from water, an alcohol, a glycol, a polyol, a water / alcohol mixture, water / glycol or water / polyol (such as water mixed with ethanol, glycerol and / or butylene glycol and / or other glycols such as xylitol and / or propanediol, etc.) from 99 / 1 to 1 / 99 (w / w), advantageously it is water as the sole solvent.

[0063] In particular, the extract is obtained by aqueous extraction. For the purposes of the present invention, "extract obtained by aqueous extraction" means any extract obtained by extraction with an aqueous solution containing more than 60% in weight, advantageously at least 70% by weight, in particular at least 80% by weight, more particularly at least 90% by weight, particularly at least 95% by weight, of water relative to the total weight of the aqueous solution, even more advantageously not containing glycol and / or polyol, particularly not containing alcohol, particularly not containing ethanol and / or butanol, more particularly containing only water.

[0064] According to a preferred method, the extract is obtained by maceration in water as the sole solvent, at a temperature above 25°C, in particular 80°C.

[0065] In a preferred embodiment, the extract according to the invention is used alone, in particular as an active ingredient. Said extract according to the invention may be in dry form, that is to say in powder form, in particular as a lyophilized powder; advantageously the extract is lyophilized.

[0066] According to another preferred embodiment, the extract according to the invention is in the form of an active ingredient in dry form, preferably in powder form, more preferably lyophilized, advantageously in association with maltodextrin, more advantageously the concentration by weight of maltodextrin is between 40% and 95%, preferably between 60% and 90%, more preferably between 75% and 85%, more preferably 80%, relative to the total weight of the active ingredient, in particular the active ingredient comprises the extract and the maltodextrin.

[0067] According to a preferred alternative embodiment, the extract according to the invention may be in liquid form and / or diluted in a solvent, preferably with an extract content of 1% to 99% (w / w), more preferably with an extract content of 5% to 60% (w / w), advantageously with an extract content of 20% to 50% (w / w), and even more advantageously with an extract content of 30% to 50% (w / w) relative to the total weight of the liquid comprising the extract and the solvent. Preferably, this solvent contains less than 20% (w / w) water, more preferably less than 5% (w / w) water, and even more preferably the solvent contains no water. Advantageously, this solvent is then of the glycol and / or glycerin type. Most preferably, this solvent is water-soluble.

[0068] According to one embodiment, the extract or composition according to the present invention is administered topically, advantageously on healthy skin and / or healthy mucous membranes. In particular, the use according to the invention is topical use, advantageously on healthy skin and / or healthy mucous membranes.

[0069] According to an advantageous embodiment, the extract or composition according to the invention is administered topically and / or the use according to the invention is topical use on specific parts of the body and / or face, advantageously chosen from the neck, torso, back, abdomen, décolleté, arms, the legs, hands, thighs, hips, buttocks, waist, groin, feet, forehead, cheeks, nose, temples, chin, lips and eye contour, the T-zone (forehead, nose and chin), advantageously an area of ​​the face and / or neck, more advantageously chosen from the forehead, cheeks, nose, temples, chin, lips, eye contour and neck.

[0070] Particularly advantageously, the specific part of the body and / or face is an area of ​​healthy tissue exhibiting sagging and / or drooping and / or an area of ​​healthy tissue lacking tone and / or firmness and / or dermal density and / or dermal thickness, and / or an area of ​​healthy skin and / or healthy mucous membrane exhibiting an uneven complexion and / or lacking brightness and / or luminosity and / or radiance.

[0071] In one embodiment of the invention, the extract according to the invention can be used alone, as an active ingredient and / or in a cosmetic composition.

[0072] The term “cosmetic ingredient” means one or more plant extracts and / or one or more natural or synthetic molecules and / or mixtures thereof intended for cosmetic use. Cosmetic ingredients are defined in particular by the International Nomenclature of Cosmetic Ingredients (INCI).

[0073] In a particular embodiment of the invention, the extract according to the invention is in the form of a cosmetic composition further comprising a cosmetically acceptable excipient, advantageously a topically acceptable cosmetic excipient.

[0074] For the purposes of the present invention, a "cosmetically acceptable" excipient means a compound and / or solvent that is topically acceptable, i.e. an ingredient suitable for topical application, non-toxic, non-irritating, not inducing an allergic response, not chemically unstable, for healthy skin and mucous membranes.The cosmetically acceptable excipient according to the invention can be selected from surfactants, preservatives, buffering agents, swelling agents, chelating agents, biocidal agents, denaturing agents, opacifying agents, pH adjusters, reducing agents, stabilizing agents, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, bactericides, odor absorbers, mattifying agents, conditioning agents, texturizing agents, gloss-enhancing agents, pigments, colorants, perfumes and chemical or mineral sunscreens, trace elements, essential oils, sweeteners, taste-modifying agents and a mixture of one or more of these excipients.

[0075] The term "cosmetic composition" means a non-therapeutic composition, that is to say, one that is not intended for therapeutic use or for the prevention and / or treatment of skin and / or mucous membranes classified as pathological by a specialist in the field such as a dermatologist, but which is intended for and / or applied, advantageously topically, to a so-called healthy part of the body, in particular to an area of ​​healthy skin and / or healthy mucous membranes, further comprising at least one cosmetically acceptable excipient.

[0076] The cosmetic composition or extract according to the invention, possibly in the form of a cosmetic ingredient, can be presented in all the galenic forms classically used for topical application, in particular topical such as liquid or solid forms or even in the form of a liquid or solid under pressure.They may in particular be formulated as a solution, aqueous or oily, a cream or aqueous gel or an oily gel, in particular in a jar or tube, in particular a shower gel, a shampoo, a milk, an emulsion, a hydrogel, a microemulsion or a nanoemulsion, in particular oil-in-water or water-in-oil or multiple or silicone, a serum, a lotion, in particular in a glass bottle, a plastic bottle or a dosing bottle or in an aerosol, an ampoule, a liquid soap, a paste, a dermatological bar, an ointment, a foam, an aerosol, a mask, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of a stick or in powders, in particular makeup.In particular, the composition is presented in the form of a serum, lotion, cream, milk, ointment, paste, mousse, emulsion, hydrogel, shower gel, aerosol, mask, stick, patch, lacquer, spray, makeup powder or wax, advantageously a cream or lotion.

[0077] In one embodiment of the invention, the composition is administered topically, advantageously on healthy skin and / or healthy mucous membranes.

[0078] In a particular embodiment of the invention, the composition according to the invention is in the form of a serum, lotion, cream, oil, milk, ointment, paste, foam, emulsion, hydrogel, shower gel, aerosol, mask, stick, patch, lacquer, spray, makeup powder or wax.

[0079] In one embodiment of the invention, the extract content of the composition according to the invention is between 1x10 4% and 10% (w / w) by weight, preferably between 1x10 3% and 10% (w / w) by weight, more preferably between 1x10 3% and 3% (w / w) by weight, even more preferably between 0.01% and 3% (w / w) by weight, in particular between 0.01% and 1% (w / w) by weight, relative to the total weight of the composition.

[0080] The cosmetic composition according to the invention may also include other ingredients having the same properties and inducing a synergistic or non-synergistic effect with the extract according to the invention, or with complementary ingredient agents. The extract may be combined with any plant extract possessing similar properties of maintaining and / or enhancing the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0081] The extract can be combined, for example, with cosmetic ingredients to prevent the appearance of pigmentation and / or to increase the radiance of the complexion, including an extract of the mushroom Inonotus obliquas marketed under the name Inolixir™ by the Applicant, an extract of Argania spinosa oil marketed under the name Arganyl™ by the Applicant, an extract of Moringa oleifera seeds marketed under the name Purisoft™ by the Applicant, and / or an extract of lychee marketed under the name Litchiderm™ as antioxidant actives, an extract of chicory marketed under the name Lox-Age™, a yeast extract marketed under the name Vitacell™, an extract of Polygonum bistorta marketed under the name Perlaura™, an extract of galangal marketed under the name Hyalufix™, a corn extract marketed under the name Deliner™, an extract of Voandzeia subterranea marketed under the name Epigenist™ by the Plaintiff;and / or with cosmetic ingredients to improve skin firmness, in particular by acting on collagen, such as a synthetic tetrapeptide marketed under the name Dermican™, an extract of Hibiscus abelmoschus marketed under the name Linefactor™, a purified pea extract marketed under the name Proteasyl™, an extract of Manilkara multinervis marketed under the name Elestan™, an extract of Khaya senegalensis marketed under the name Collalift™18, an extract of Argan pulp marketed under the name Argassiential™, retinol, vitamin C, an extract of Davilla rugosa marketed under the name Collguard™, an extract of hydrolyzed soy protein marketed under the name Phytokine™;and / or with cosmetic ingredients active on sensitive skin, including deoiled ungerminated Moringa oleifera seed protein extract marketed under the trade name Purisoft®, a Cestrum latifolium plant extract marketed under the name Symbiocell™, a butter extracted from the fruit of the Irvingia gabonensis tree marketed under the name Irwinol™, an Eperua falcata root extract marketed under the name Eperuline™, a Nacetyl-L-Tyrosyl-L-Prolyl-L-Phenylalaninamide peptide (INCI: Acetyl Tetrapeptide) marketed under the name Skinasensyl™, and / or with cosmetic ingredients active on the skin and / or mucosal microbial flora and / or active on the skin barrier function, including moisturizing and / or soothing agents, among which is an oligosaccharide obtained by enzymatic synthesis marketed by the company Solabia under the name BioEcolia™ or; an alpha-glucooligosaccharide complex marketed by the same company under the name Ecoskin™, an extract of Argania spinosa (Lipofructyl™ Argan), a mixture of ceramides (Sphingoceryl™ VEG), purifying extracts of Boldo (Betapur™), products based on inulin or fructooligosaccharides, extracts of bifidobacteria or an extract of Orthosiphon stamineus to combat oily skin (MAT-XS™ Bright), a natural honey extract marketed by the Applicant under the name Melhydran™ for its moisturizing properties, a flax extract marketed under the name Oligolin™ by the Applicant, a yeast extract modified by biotechnology and marketed by the Applicant under the name Relipidium™, a Pueraria lobata root extract marketed under the name Inhipase™ by the Applicant,a beta-glucan derivative from baker's yeast marketed by Mibelle under the name CM-Glucan Forte™ and / or an extract of Mirabilis jalapa marketed under the name Pacifeel™ by Sederma. The extract can be combined, for example, with anti-aging cosmetic ingredients such as an extract of Peucedanum Graveolens marketed by the Applicant under the name Lys'Lastine®V; an extract of Hippophae Rhamnoides marketed by the Applicant under the name RNAge™; an extract of Fucus Vesiculosus marketed by the Applicant under the name Seanactiv™; an extract of Nephelium Lappaceum marketed by the Applicant under the names Nephoria® and Nephydrat®; and an extract of Schizandra Chinensis marketed by the Applicant under the name Sqisandryl®.

[0082] The cosmetic process

[0083] A second object relates to a non-therapeutic cosmetic care process comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae, in particular as described above, or of a cosmetic composition comprising it, in particular as described above, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0084] In one embodiment of the invention, the method according to the invention is for maintaining and / or improving the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes.

[0085] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the firmness of healthy skin and / or healthy mucous membranes.

[0086] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the tone of healthy skin and / or healthy mucous membranes.

[0087] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the density of the dermis of healthy skin and / or healthy mucous membranes.

[0088] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the thickness of the dermis of healthy skin and / or healthy mucous membranes.

[0089] In another embodiment of the invention, the method according to the invention for improving and / or maintaining the biomechanical properties of healthy skin and / or healthy mucous membranes is by increasing and / or maintaining collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0090] Advantageously, the process according to the invention is for increasing and / or maintaining the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0091] Advantageously, the process according to the invention is for maintaining and / or increasing the synthesis of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0092] Advantageously, the process according to the invention is for increasing and / or maintaining collagen synthesis and / or inhibiting collagen degradation, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0093] Advantageously, the process according to the invention is for inhibiting the degradation of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0094] Advantageously, the method according to the invention is for inhibiting collagen degradation by decreasing the amount of matrix metalloprotease(s) (MMP), particularly matrix metalloprotease(s) of type I (MMPI) and / or type III (MMP3), preferably said decrease is by decreasing the synthesis and / or secretion of matrix metalloprotease(s) (MMP), particularly of type I (MMPI) and / or type III (MMP3).

[0095] In an alternative embodiment of the invention, the process according to the invention is further to maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, preferably by increasing and / or maintaining the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

[0096] In an advantageous embodiment of the invention, the area of ​​healthy skin and / or healthy mucous membranes is an area selected from an area of ​​the body and / or face, preferably the neck, torso, back, abdomen, décolleté, arms, legs, hands, thighs, hips, buttocks, waist, groin, feet, the forehead, cheeks, nose, temples, chin, lips and eye contour, the T-zone (forehead, nose and chin), advantageously an area of ​​the face and / or neck, more advantageously chosen from the forehead, cheeks, nose, temples, chin, lips, eye contour and neck.

[0097] Particularly advantageously, the area of ​​healthy skin and / or healthy mucous membranes is an area of ​​healthy tissue exhibiting sagging and / or drooping and / or an area of ​​healthy tissue lacking tone and / or firmness and / or density and / or thickness of the dermis and / or an area of ​​healthy skin and / or healthy mucous membranes exhibiting an uneven complexion and / or lacking brightness and / or luminosity and / or radiance.

[0098] In an even more advantageous embodiment, the method according to the invention comprises: - the selection of an area of ​​healthy skin and / or healthy mucous membranes of an individual for which one wishes to improve and / or maintain the biomechanical properties of the healthy skin and / or healthy mucous membranes, advantageously for which one wishes to maintain and / or improve the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, of the healthy skin and / or healthy mucous membranes; - the topical application to this area of ​​healthy skin and / or healthy mucous membranes of the extract according to the invention or of a cosmetic composition comprising it, advantageously in an acceptable cosmetic quantity, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes, advantageously to maintain and / or improve the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes.

[0099] In an alternative embodiment, the method according to the invention comprises: - selecting an area of ​​healthy skin and / or mucous membranes of an individual for which it is desired to maintain and / or improve the radiance of the complexion of the healthy skin and / or mucous membranes, advantageously for which it is desired to maintain and / or improve the radiance and / or luminosity of the healthy skin and / or mucous membranes. - applying topically to this area of ​​healthy skin and / or mucous membranes the extract according to the invention or a cosmetic composition comprising it, advantageously in a cosmetically acceptable quantity, to maintain and / or improve the radiance of the complexion of the healthy skin and / or mucous membranes, advantageously to maintain and / or improve the radiance and / or luminosity of the healthy skin and / or mucous membranes.

[0100] In one embodiment of the invention, the cosmetic care process according to the invention is characterized in that the extract and / or composition is / are as defined above.

[0101] Preferably, the use according to the invention or the cosmetic process according to the invention includes the daily topical application of a composition according to the invention, preferably twice a day for a period of at least 14 days, preferably at least 28 days and preferably at least 56 days.

[0102] Other objects, features and advantages of the invention will become clear to a person skilled in the art upon reading the explanatory description which refers to examples which are given only by way of illustration and which shall in no way limit the scope of the invention.

[0103] The examples form an integral part of the present invention, and any feature appearing new compared to any prior art, as described in the whole including the examples, forms an integral part of the invention in its function and generality. Thus, each example has general application.

[0104] Unless otherwise specified, temperature is expressed in degrees Celsius, ambient temperature is between 20°C and 25°C, and pressure is atmospheric pressure. Percentages are by weight over total volume (w / v).

[0105] The results are expressed as follows: Mean + / - Standard deviation. The abbreviation "NA" denotes a result not applicable. The significance level was set at 5% (p<0.05) according to commonly used statistical methods known to those skilled in the art, in particular the Student's t-test or the ANOVA test. EXAMPLES

[0106] Example 1: Method of preparing the extract of Lysimachia christinae according to the invention

[0107] Example (a) Liquid aqueous extract: The dried aerial parts of the plant Lysimachia christinae were ground and extracted with water (the sole solvent, with a content of 7.5% by weight of dry plant relative to the total weight of plant and solvent) for 1 hour at 80°C. The resulting extract was then filtered and used as is for the various evaluations. The extract is in liquid form.

[0108] Example 1b) Powdered extract: The extract obtained in example 1a) has been lyophilized. It is in powder form.

[0109] Example (a) Powder composition: Maltodextrin was added to the filtered extract obtained in Example (a). The resulting composition was then atomized to give a powder composed of 80% maltodextrin and 20% Lysimachia christinae extract by weight of the total composition. The composition is in powder form.

[0110] Example Id) example of a cosmetic formulation according to the invention:

[0111] The ingredients of phases A, B, and C were mixed separately at room temperature. The contents of phase A were added to the contents of phase B, and then the mixture was blended with phase C while stirring. The pH was then adjusted with phase D (citric acid solution) to obtain a pH value between 4.8 and 5. Finally, phase E was added to the mixture and homogenized with an Ultra Turrax®, taking care not to incorporate any air.

[0112] [Tables 1] Trade Name INCI Name % Phase A Glycerin 99-5 Glycerin 5.00 1,3-Butanediol Butylene Glycol 10.00 Verdessence™ Xanthan Gum Xanthan Gum 2.00 Phase B Water Water 60.65 Sodium Benzoate Sodium Benzoate 0.25 Dermosoft 1388 Eco (Evonik) Glycerin, Water, Sodium Levulinate, Sodium Anisate 1.00 Phase C Dehymuls® PGPH Polyglyceryl-2 Dipolyhydroxystearate 1.00 Cetiol® CC Dicaprylyl Carbonate 6.00 Cetiol® RLF Caprylyl Caprylate / Caprate 10.00 Plantapon® LC 7 Laureth-7 Citrate 0.50 Phase D Citric Acid (50% aqueous solution) Citric Acid, Water 0.35 Phase E Water Water 3.00 Extract of Lysimachia Christinae se Ion the example on - 0.25 Total - 100.00 Example 2: Stimulation of type I collagen synthesis

[0113] Normal human dermal fibroblasts obtained from breast biopsies of a 26-year-old donor were cultured in monolayers and grown to confluence in 96-well plates in fibroblast growth medium (Dulbecco's modified Eagle medium (DMEM)) supplemented with 10% fetal bovine serum (F10), glucose, L-glutamine, and antibiotics for 96 hours at 37°C and under 5% CO2. The confluent fibroblasts in the defined fibroblast growth medium were treated for 48 hours with or without (untreated control) the product of the invention described in Example 1b). Vitamin C at 50 pM was used as a positive control.

[0114] The culture medium was then removed and an ammonium hydroxide lysis solution was added. The resulting cell lysates were collected for DNA assay. In parallel, after saturating the matrix with a PBS (Phosphate Buffer Saline) / BSA (Bovine Serum Albumin) solution, incubation was performed with a primary anti-collagen I antibody (commercially available from Novotec) followed by a secondary antibody conjugated to europium (commercially available from Revvity). The fluorescence intensity was read on a Perkin Elmer multi-mode or fluorescence plate reader.

[0115] The results obtained are shown in Table 2 below and are expressed as a percentage of the deposited collagen I rate relative to the amount of DNA measured in the cells. The untreated control was set at 100%.

[0116] [Tables2] Products tested Average Collagen I versus control (%) Statistics Control 100 + / - 17.8 Not Applicable Vitamin C 50pM 216.13+ / -35.61 p<0.01 Lysimachia christinae extract according to exem pie 1b at 0.01% (w / v; weight / volume) 183.4+ / - 43.5 p<0.01

[0117] The number of replicates is n=6.

[0118] The significance threshold was set at 5% (p<0.05).

[0119] Statistical tests performed: Student's t-test (positive control versus untreated control). Extract from example 1b) (lyophilized Lysimachia christinae extract) versus control (One Way ANOVA Holm-Sidack method; significance).

[0120] Conclusion: The product of the invention described in Example 1b) (formulation according to the invention) induced a significant improvement in the synthesis of type I collagen by fibroblasts compared to the control.

[0121] Example 3: Inhibition of the secretion of matrix metalloproteinases I (MMPI) and III (MMP3)

[0122] Example 3a): Inhibition of matrix metalloproteinase I (MMPI) secretion

[0123] Normal human dermal fibroblasts obtained from abdominal biopsies of a 34-year-old donor were cultured in monolayers and grown to confluence in 12-well plates in a fibroblast growth medium (fibroblast expansion base medium commercially available from Thermo Fisher) supplemented with 10% fetal bovine serum (F 10), glucose, L-glutamine, and antibiotics for 96 hours at 37°C and under 5% CO2. The confluent fibroblasts in a fibroblast growth medium (Dulbecco's modified Eagle medium (DMEM)) were initially treated with or without (untreated control) the product of the invention described in Example 1b for 24 hours.The fibroblasts were then incubated for 48 hours without any other product (control), with the histone deacetylase (HDAC) inhibitor sodium butyrate (NaBu) in the presence of Lysimachia christinae extract (Lysimachia christinae conditions in the results table) or without it (NaBu condition in the results). The culture supernatants were then collected, and 100pL of each sample, as well as each point of the standard curve, were transferred to another microplate in which a specific antibody for human MMP-1 (commercially available in kit form from Sigma) had been immobilized.

[0124] 1OOpL of MMP-1 standards and samples were placed in the wells and the assembly was incubated for 2.5 h at room temperature; the MMPI present in a sample was bound to the wells by the immobilized antibody.

[0125] The wells were washed using the wash buffer contained in the kit sold by SIGMA, dried, and 100pL of biotinylated human anti-MMP-1 antibody were added, and the whole was incubated for 1h at room temperature. After washing away the unbound biotinylated antibody, 100pL of HRP (horseradish peroxidase) conjugated streptavidin was added to each well, and the whole was incubated at room temperature for 45 minutes. The wells were washed again, and 100pL of an HRP substrate solution was added to the wells, and the color developed proportionally to the amount of bound MMP-1 in each well for 30 minutes. 50pL of the stop solution (from blue to yellow) were added to each well, and the color intensity was measured by spectrophotometer at 450 nm.

[0126] The results obtained are shown in Table 3 below and are expressed as a percentage of the MMP-1 enzyme, with the NaBu condition representing the maximum of 100% protein secreted.

[0127] [Tables3] Products tested Percentage of MMP-1 var sus Control NaBu Statistics NaBu 100 + / - 9 Not Applicable Lysimachia Christinae extract according to example 1b at 0.005% (w / v; weight / volume) 32 + / - 0 p<0.05 Lysimachia Christinae extract according to example 1b at 0.01% (w / v; weight / volume) 9 + / - 1 p<0.05

[0128] The significance threshold was set at 5% (p<0.05).

[0129] The number of replicates is n=3.

[0130] Statistical test performed: Extract from example 1b) versus NaBu (One Way ANOVA Dunnet method).

[0131] Conclusion: The composition according to example 1b) (formulation according to the invention) showed a significant inhibition of matrix metalloproteinase type I (MMPI) secretion in a concentration-dependent manner, consequently demonstrating the inhibition of collagen degradation.

[0132] Example 3b): Inhibition of metalloproteinase III (MMP3) secretion

[0133] The same protocol as in Example 3a) was used but with the use of a specific anti-MMP-3 human antibody instead of the specific anti-MMP-1 antibody (commercially available in kit form from Sigma).

[0134] The results obtained are shown in Table 4 below and are expressed as a percentage of the MMP-3 enzyme, with the NaBu condition representing the maximum of 100% protein secreted.

[0135] [Tables4] Products tested Percentage of MMP-3 versus sus Control NaBu Statistics NaBu 100 + / - 4 Not Applicable Lysimachia christinae extract according to example 1b at 0.0025% (w / v; weight / volume) 73+ / - 11 p<0.05 Lysimachia christinae extract according to example 1b at 0.005% (w / v; weight / volume) 44 + / - 6 p<0.001 Extract of Lysimachia christinae according to example 1b at 0.01% (w / v; weight / volume) 20 + / - 2 p<0.001

[0136] The number of replicates is n=3;

[0137] Statistical test performed: Extract from example 1b) versus NaBu (One Way ANOVA Holm Sidack method).

[0138] Conclusion: The product of the invention according to Example 1b) (formulation according to the invention) has shown a significant inhibition of matrix metalloproteinase type III (MMP3) secretion in a concentration-dependent manner, consequently demonstrating the inhibition of collagen degradation.

[0139] Example 4: Clinical improvement of skin characteristics after application of the composition of the invention according to example Id)

[0140] The improvements in skin quality resulting from the application of the composition of the invention according to Example Id) were evaluated in a clinical test. The objective of this test was to evaluate the effect of the composition of the invention on the biomechanical properties of the skin and / or mucous membranes, in particular skin firmness, tone, and radiance, independently.

[0141] Protocol. The study was designed and conducted as a randomized, double-blind trial in which the efficacy of the composition of the invention was compared to the efficacy of a placebo. Two groups of 31 Chinese volunteers aged 33 to 55 years were recruited. One group applied the composition according to Example Id) formulated at 0.25% (% w / w), and a second group applied a formulation not containing the composition according to Example Id) (placebo). Both groups applied the formulations to all areas of the face, twice a day for 56 days (corresponding to two months). The volunteers' skin was healthy.

[0142] The evaluation of the improvement in clinical parameters was carried out using an Indentometer® for skin firmness, a Cutometer® for skin tone, and a Glossimeter® for skin radiance (these devices are notably marketed by Courage and Khazaka). Measurements were taken at the beginning of the study (D0), and / or after 14 days (D14), and / or after 28 days (D28), and / or after 56 days (D56) of application.

[0143] The results are expressed as percentage improvements in the measured parameters compared to the same parameters measured at the beginning of the study (D0). The improvement provided by the composition according to example Id) is also measured compared to the effects measured with the placebo formulation.

[0144] A statistical analysis of each formulation was performed as follows; all data were analyzed to confirm the normality of the distribution using the Shapiro-Wilk test. The following tests were used to compare the change in clinical parameters after application of the formulation containing the composition according to the invention and the placebo formulation: - For comparisons where the normality of both data sets (product of the invention and placebo) was validated, a paired Student's t-test or an unpaired Student's t-test was used, - if there was no validation of normality, a Wilcoxon Signed-Rank test or a Whitney-Mann Rank test was used.

[0145] Example 4a: Improvement of skin tone (Cutometer®)

[0146] The Cutometer® measures the mechanical properties of the skin by recording the deformation of the skin through suction and its return to its original state. The skin's tone, i.e., its firmness, was measured by performing a series of deformations (minimum 10) and recording the areas of deformation, where the smaller the amplitude of deformation, the less toned the skin.

[0147] [Tables5] Evolution of parameter in % / D0 Formulati on place bo Composition according to Ex Id) Differences in improvement between composition according to Ex Id) and placebo formulation Statistics Formulati on placeb o / D0 Statistics Composition according to Ex Id) / to D 0 Statistics Composition according to Ex Id) / formulation plac ebo D14 -7.9% +28% +36% p<0.05 p<0.001 p<0.001 D28 +15% +44% +30% p<0.001 p<0.001 p<0.001 D56 +11% +37% +26% p<0.05 p<0.01 p<0.01

[0148] Conclusion: The composition according to example Id) (formulation according to the invention) showed a significant improvement in skin tone compared to the beginning of the study (D0) at all measurement times (D14, D28 and D56), and a statistically significant improvement superior to that provided by the placebo formulation.

[0149] Example 4b: Improvement of skin firmness (Indentometer®)

[0150] The Indentometer® measures skin firmness by measuring the depth of skin deformation using a ball, where the shallower the depth, the firmer the skin.

[0151] [Tableauxô Evolution of Formulation Composition Differences in a Statistics Statistics Statistics u parameter on placebo on according to E improvement between Formulation Composition Composition in % / D0 ox Id) re composition placebo / D n according to Ex 1 n according to Ex 1 according to Ex Id) e 0 d) / at D0 t pl acebo formulation d) / placebo formula D28 -11% -17% -6.1% p<0.001 p<0.001 p<0.01 D56 -4.7% -12% -7.3% p<0.05 p<0.001 p<0.05

[0152] Conclusion: The composition according to example Id) (formulation according to the invention) showed a significant improvement in skin firmness compared to the beginning of the study (DO) at D28 and D56, and a statistically significant improvement superior to that provided by the placebo formulation, and this from one month of application (D28).

[0153] Example 4c: Improvement of skin radiance (Glossimeter®)

[0154] The Glossimeter® allows the radiance of the skin and / or mucous membranes to be measured by projecting a light onto them and measuring the reflection of this light at a very precise angle, where the greater the reflection, the more radiant the skin and / or mucous membrane is.

[0155] [Tables?] Parameter evolution in % / D0 Placebo formulation Composition according to Ex 1 d) Differences in improvement between composition according to Ex Id) and placebo formulation Statistics Placebo formulation / D0 Statistics Composition according to Ex 1 d) / at D0 Statistics Composition according to Ex 1 d) / placebo formulation D56 +12% +18% +6.2% p<0.001 p<0.001 p<0.001

[0156] Conclusion: The composition according to example Id) (formulation according to the invention) showed a significant improvement in the radiance of the complexion, the luminosity, or the brightness of the skin, compared to the beginning of the study (D0) after 2 months of application (D56).

Claims

Demands

1. Non-therapeutic cosmetic use of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

2. Use according to claim 1 to maintain and / or improve the firmness and / or tone and / or density of the dermis and / or thickness of the dermis, of healthy skin and / or healthy mucous membranes, preferably the firmness of healthy skin and / or healthy mucous membranes.

3. Use according to claim 1 or 2 to increase and / or maintain the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

4. Use according to any one of the preceding claims to maintain and / or increase collagen synthesis, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

5. Use according to claim 3 or 4 to inhibit the degradation of collagen, particularly type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers, preferably by decreasing the amount of matrix metalloproteinase(s) (MMP), particularly type I and / or type III matrix metalloproteinase(s).

6. Use according to any of the preceding claims to further maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, advantageously the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

7. Use according to any one of the preceding claims, characterized in that it is a topical use.

8. Use according to any one of the preceding claims, characterized in that the extract of Lysimachia christinae is an extract of aerial parts, preferably the leaves.

9. Use according to any one of the preceding claims, characterized in that the extract is obtained by extraction in a solvent or mixture of protic polar solvent(s), advantageously in water, an alcohol, a glycol, a polyol or a mixture thereof, advantageously also in water as the sole solvent.

10. Use according to any one of the preceding claims, characterized in that the extract is in the form of an active ingredient in dry form, preferably in powder form, more preferably lyophilized, advantageously in association with maltodextrin, more advantageously the concentration by weight of maltodextrin is between 40% and 95%, preferably between 60% and 90%, more preferably between 75% and 85%, more preferably 80%, relative to the total weight of the active ingredient.

11. Use according to any one of the preceding claims, characterized in that the extract is in the form of a cosmetic composition further comprising a cosmetically acceptable excipient.

12. Use according to claim 11, characterized in that the extract content of the composition is between 1x104% and 10% (w / w) by weight, preferably between 1x10 3% and 10% (w / w) by weight, more preferably between 1x10 3% and 3% (w / w) by weight, even more preferably between 0.01% and 3% (w / w) by weight, in particular between 0.01% and 1% (w / w) by weight, relative to the total weight of the composition.

13. Use according to any one of claims 11 or 12, characterized in that the composition is administered topically.

14. Use according to any one of claims 11 to 13, characterized in that the composition is in the form of a serum, lotion, cream, oil, milk, ointment, paste, foam, emulsion, hydrogel, shower gel, aerosol, mask, stick, patch, lacquer, spray, makeup powder or wax.

15. A non-therapeutic cosmetic treatment method comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae or a cosmetic composition comprising it, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

16. A method according to claim 15, for maintaining and / or improving the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes.

17. A method according to claim 15 or 16 for increasing and / or maintaining the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

18. A method according to any one of claims 15 to 17 for further maintaining and / or improving the radiance of the complexion of healthy skin and / or healthy mucous membranes, advantageously the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

19. A method according to any one of claims 15 to 18, characterized in that the area of ​​healthy skin and / or healthy mucous membranes is chosen from a healthy area of ​​the body and / or face, preferably the neck, torso, back, abdomen, décolletage, arms, legs, hands, thighs, hips, buttocks, waist, groin, feet, forehead, cheeks, nose, temples, chin, lips and eye contour, the T-zone (forehead, nose and chin), advantageously an area of ​​the face and / or neck, more advantageously chosen from the forehead, cheeks, nose, temples, chin, lips, eye contour and neck.

20. A process according to any one of claims 15 to 19, characterized in that the extract is as defined in any one of claims 8 to 10 and / or the composition is as defined in any one of claims 11 to 14.